Five Lives Raises €2M for AI Alzheimer's Therapy

Digital therapeutics innovator Five Lives has successfully closed a funding round totaling €2 million, with a significant portion coming from strategic investors Open CNP (the investment arm of CNP Assurances), 50 Partners, and Family Ventures. The company is further bolstering its capital through a public crowdfunding initiative on Sowefund, aiming to add between €300,000 and €500,000 to its war chest. This infusion of capital is earmarked for expanding its commercial reach across France, the UK, and the US, and for funding crucial second-phase clinical trials.

Founded in 2021 by Xavier Louis and Sylvain Piquet, Five Lives is pioneering a scientifically validated digital intervention for individuals facing Alzheimer's disease and cognitive decline. The company's name draws inspiration from the landmark FINGER study, which highlighted the profound impact of a multi-faceted approach—integrating cognitive exercises, physical activity, nutritional guidance, cardiovascular health management, and social engagement—on reducing dementia risk by nearly half and preserving cognitive function equivalent to five years.

The company's product suite includes two distinct applications. Five Lives Brain Health serves as a proactive prevention tool for individuals at elevated risk but not yet diagnosed. Complementing this, Five Lives Care, launched in early 2026, offers a therapeutic solution for patients experiencing mild cognitive impairment. These platforms deliver a rich array of content, featuring over 500 adapted physical activity videos, engaging memory and attention games, language exercises, and personalized lifestyle recommendations covering sleep, nutrition, and social interaction. A key innovation is the real-time adjustment of difficulty levels, tailoring each session to the user's specific cognitive profile.

The efficacy of the Five Lives platform has been rigorously established through a randomized clinical trial involving 180 participants across seven hospitals in the UK and France. The study demonstrated that a mere three months of engagement with the application led to statistically significant improvements in executive functions and overall quality of life. This scientific validation is a cornerstone of the company's strategy, differentiating it from general wellness applications. As CEO Xavier Louis emphasizes, "Neurologists won't recommend you if you haven't been validated."

Currently, Five Lives Care is available at €30 per month and has garnered recommendations from neurologists and geriatricians in leading French and British medical institutions. The company's medium-term ambition is to secure reimbursement from French social security via the PECAN digital therapy program, with a target of 2027. This aligns with France's HAS reimbursement rate for digital therapies, set at €135 per month. The market precedent is strong, with a German competitor already achieving over 5,000 monthly prescriptions and exceeding €1 million in its first year, benefiting from similar social security reimbursement.

Looking ahead, Five Lives is integrating artificial intelligence to further refine session personalization, akin to a bespoke fitness regimen tailored to individual cognitive needs. The company projects substantial revenue growth, forecasting €400,000 for 2025, escalating to €1 million in 2026, and aiming for €5-10 million in 2027 upon securing reimbursement. The long-term vision is ambitious: to treat 500,000 patients annually by 2030, generating €100 million in revenue and establishing itself as the global leader in brain health solutions. Early traction is promising, with 200,000 cumulative downloads and 5,000 active patients on the therapeutic app within its initial two months post-launch, signaling robust demand in the rapidly expanding digital therapeutics sector.